Alkem Laboratories share price
You have to be logged in to add this to Watchlist.- ₹5,674.30(0.54%)November 7, 2025 15:43:34 PM IST
- NSE
- BSE
- Vol : 228.90K (NSE + BSE)Last 20 day avg : 128.36 K
Alkem Laboratories is trading 0.54% upper at Rs 5,674.30 as compared to its last closing price. Alkem Laboratories has been trading in the price range of 5,681.90 & 5,571.90. Alkem Laboratories has given 0.17% in this year & 1.96% in the last 5 days. Alkem Laboratories has TTM P/E ratio 25.85 as compared to the sector P/E of 23.79.There are 18 analysts who have initiated coverage on Alkem Laboratories. There are 3 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 664.26 Crores in its last quarter.Listed peers of Alkem Laboratories include Lupin (0.76%), Abbott India (-2.22%), Alkem Laboratories (0.54%).The Mutual Fund holding in Alkem Laboratories was at 16.94% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Alkem Laboratories was at 9.47% in 30 Sep 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Nov 07, 2025, 10:27 PM UTC
- BetaLow volatility0.75Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.12The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.80Annual dividends as a percentage of the stock price.
- P/BHigher than historical values5.63The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values29.54Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates overvaluation3.08The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in June quarter by 11.19% from Rs 3371.14 crore to Rs 3031.82 crore, year-on-year
- The company has grown its June quarter profit by 21.85% from Rs 545.16 crore to Rs 664.26 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 5,730.90
- R2
- 5,834.85
- R3
- 5,952.70
- S1
- 5,509.10
- S2
- 5,391.25
- S3
- 5,287.30
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Lupin | Moderately Bullish | 1,970.85 | 0.76 | 90,020.98 | 27.27 | 5.19 | 0.41 | 11.80 |
| Abbott India | Bearish | 28,825.00 | -2.22 | 61,251.12 | 53.21 | 17.78 | 1.34 | 3.73 |
| Alkem Laboratories | Bullish | 5,674.30 | 0.54 | 68,008.65 | 26.62 | 4.81 | 0.93 | 4.83 |
| Glaxosmithkline Pharmaceutical | Bearish | 2,590.55 | -0.47 | 43,935.28 | 60.53 | 28.67 | 1.27 | 0.13 |
| Glenmark Pharmaceuticals | Moderately Bearish | 1,825.00 | 0.79 | 51,501.65 | 37.95 | 5.69 | 0.14 | 7.90 |
- Promoter(s) holds a high stake in the company at 51.20%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has increased by 0.36 percentage points from previous quarter
- Mutual Funds holding has increased by 0.27 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-11-13 | Quarterly Results |
| 2025-08-12 | Quarterly Results |
| 2025-05-29 | Audited Results & Final Dividend |
| 2025-02-07 | Quarterly Results & Interim Dividend |
| 2024-11-13 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE540L01014
- BSE Code539523
- NSE CodeALKEM
Alkem Laboratories is trading at 5674.30 as on Fri Nov 07 2025 10:13:34. This is 0.54% upper as compared to its previous closing price of 5643.65.
The market capitalization of Alkem Laboratories is 68008.65 Cr as on Fri Nov 07 2025 10:13:34.
The average broker rating on Alkem Laboratories is Hold. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 4 analysts have given a buy rating
- 7 analysts have given a hold rating
- 3 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Alkem Laboratories is 5960.75 whereas the 52 wk low is 4498.90
Alkem Laboratories can be analyzed on the following key metrics -
- TTM P/E: 25.85
- Sector P/E: 23.79
- Dividend Yield: 0.80%
- D/E ratio: -
Alkem Laboratories reported a net profit of 2165.48 Cr in 2025.
The Mutual Fund Shareholding was 16.94% at the end of 30 Sep 2025.